7RU2 image
Entry Detail
PDB ID:
7RU2
EMDB ID:
Keywords:
Title:
SARS-CoV-2-6P-Mut7 S protein (asymmetric)
Biological Source:
PDB Version:
Deposition Date:
2021-08-16
Release Date:
2022-08-24
Method Details:
Experimental Method:
Resolution:
3.00 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Spike glycoprotein
Mutations:R682G, R683S, R685S, V705C, F817P, T883C, A892P, A899P, A942P, K986P, V987P
Chain IDs:A, B, C
Chain Length:1280
Number of Molecules:3
Biological Source:Severe acute respiratory syndrome coronavirus 2
Ligand Molecules
Primary Citation
Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways.
Iscience 25 104914 104914 (2022)
PMID: 35971553 DOI: 10.1016/j.isci.2022.104914

Abstact

The rapid spread of SARS-CoV-2 variants poses a constant threat of escape from monoclonal antibody and vaccine countermeasures. Mutations in the ACE2 receptor binding site on the surface S protein have been shown to disrupt antibody binding and prevent viral neutralization. Here, we used a directed evolution-based approach to engineer three neutralizing antibodies for enhanced binding to S protein. The engineered antibodies showed increased in vitro functional activity in terms of neutralization potency and/or breadth of neutralization against viral variants. Deep mutational scanning revealed that higher binding affinity reduces the total number of viral escape mutations. Studies in the Syrian hamster model showed two examples where the affinity-matured antibody provided superior protection compared to the parental antibody. These data suggest that monoclonal antibodies for antiviral indications would benefit from affinity maturation to reduce viral escape pathways and appropriate affinity maturation in vaccine immunization could help resist viral variation.

Legend

Protein

Chemical

Disease

Primary Citation of related structures